Successful use of recombinant factor VIIa (NovoSeven®) during cardiac surgery in a pediatric patient with congenital factor XI deficiency
Pediatric Cardiology, cilt.29, sa.1, ss.220-222, 2008 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 29 Sayı: 1
- Basım Tarihi: 2008
- Doi Numarası: 10.1007/s00246-007-9081-3
- Dergi Adı: Pediatric Cardiology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.220-222
- Anahtar Kelimeler: factor XI deficiency, recombinant factor VIIa, heart surgery
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
We report our experience with the use of recombinant activated factor VII (rFVIIa) during cardiac surgery in a 4.5-year-old boy with severe congenital FXI deficiency and a congenital heart disease. After weaning the patient from cardiopulmonary bypass, the first intravenous dose of rFVIIa (90 μg/kg) was administered. This same dosage was repeated eight more times, at 2- to 4-hour intervals postoperatively. There was no bleeding during and after surgery. rFVIIa treatment may be used successfully in children with severe FXI deficiency in major operations such as open heart surgery. © 2007 Springer Science+Business Media, LLC.